Utility of I-124 PET/CT in identifying radioiodine avid lesions in differentiated thyroid cancer: a systematic review and meta-analysis

Autor: Wael Marashdeh, Paul W. Ladenson, Prasanna Santhanam, David Taïeb, Lilja B. Solnes
Přispěvatelé: Johns Hopkins University School of Medicine [Baltimore], Service de médecine nucléaire [Marseille], Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Zdroj: Clinical Endocrinology
Clinical Endocrinology, Wiley, 2017, 86 (5), pp.645-651. ⟨10.1111/cen.13306⟩
Clinical Endocrinology, 2017, 86 (5), pp.645-651. ⟨10.1111/cen.13306⟩
ISSN: 0300-0664
1365-2265
DOI: 10.1111/cen.13306⟩
Popis: International audience; Introduction Diagnostic I-123 scans have been shown to underestimate the disease burden in differentiated thyroid cancer (DTC) when compared to I-131 post-treatment scans, especially in children and patients who have had prior radioiodine (RAI) therapy and/or distant metastasis. I-124 PET/CT has been shown to be highly effective in imaging DTC-related metastatic disease. Methods We performed a systematic review and meta-analysis of studies investigating the sensitivity and specificity of I-124 PET/CT in identifying lesions amenable to RAI therapy as confirmed by I-131 post-treatment scanning. Results There were 141 patients and 415 lesions of DTC identified altogether. There was significant heterogeneity in the individual studies. The pooled sensitivity of the I-124 PET/CT in detecting lesions of differentiated thyroid cancer amenable to I-131 therapy was 94Á2% (91Á3–96Á4% CI, P < 0Á01), and the pooled specificity was 49Á0% (34Á8–63Á4% CI, P < 0Á01). The pooled positive likelihood ratio (LR) was 1Á43 (1Á05–1Á94 CI), and the pooled negative LR was 0Á28 (0Á15–0Á53 CI). Overall, the diagnostic odds ratio was 7Á90 (3Á39–18Á48 CI). There were a small but increased number of lesions identified by I-124 PET/CT that was not detected on post-treatment scan. Conclusion I-124 PET/CT is a sensitive tool to diagnose RAI avid DTC lesions, but also detects some new lesions that are not visualized on the post-treatment I-131 scan. Further, carefully designed dosimetric studies may be required to fully establish the role of I-124 PET CT for identifying potential lesions for I-131 therapy. I-124 PET/CT in patients with DTC may have other applications in specific clinical situations.
Databáze: OpenAIRE
Externí odkaz: